Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million - Candlesense
RPRX Funding

Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million

(NASDAQ:RPRX) NEW YORK and WALTHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Zenas BioPharma, Inc. (Nasdaq: ZBIO) today announced that Royalty Pharma will provide up to $300 million in funding in exchange for a royalty on sales of obexelimab.

Related Questions

How will the $300 million royalty financing deal affect Royalty Pharma’s cash flow and earnings outlook? What impact will the obexelimab funding agreement have on Zenas BioPharma’s valuation and share price volatility? How does this royalty arrangement compare to similar financing structures in the biotech sector and what are the potential dilution or upside risks for investors?
Find similar articles on Candlesense globenewswire